Erratum: Fcγ 3RIIB in autoimmunity and infection: Evolutionary and therapeutic implications (Nature Reviews Immunology (2010) 10 (328-343) DOI: 10.1038/nri2762);FcγRIIB in autoimmunity and infection: Evolutionary and therapeutic implications

Nature Reviews Immunology

Volumn 10, Issue 5, 2010, Pages 328-343

  Smith, Kenneth G C ^a   Clatworthy, Menna R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; PNEUMOCOCCUS VACCINE; RITUXIMAB; CYTOKINE; FC RECEPTOR; FCGR2B PROTEIN, HUMAN;

AUTOIMMUNITY; BINDING AFFINITY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME REGULATION; ETHNIC DIFFERENCE; GENETIC VARIABILITY; GOODPASTURE SYNDROME; HUMAN; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; MALARIA; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SALMONELLA TYPHIMURIUM; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BIOSYNTHESIS; DENDRITIC CELL; DRUG ANTAGONISM; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GENETIC VARIATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALARIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG;

EID: 77951610700     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2821     Document Type: Erratum

References (166)

1. Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nature Rev. Immunol. 8, 34-47 (2008).
2. Perez, L. G., Costa, M. R., Todd, C. A., Haynes, B. F. & Montefiori, D. C. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J. Virol. 83, 7397-7410 (2009).
3. Verma, A. et al. Analysis of the Fcγ receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin. Vaccine Immunol. 16, 1405-1412 (2009).
4. Bharadwaj, D., Stein, M. P., Volzer, M., Mold, C. & Du Clos, T. W. The major receptor for C-reactive protein on leukocytes is fcγ receptor II. J. Exp. Med. 190, 585-590 (1999).
5. Lu, J. et al. Structural recognition and functional activation of FcγR by innate pentraxins. Nature 456, 989-992 (2008).
6. Sinclair, N. R. Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit long-lasting IgG immunological priming after removal of the Fc fragment. J. Exp. Med. 129, 1183-1201 (1969).
7. Sidman, C. L. & Unanue, E. R. Control of B-lymphocyte function. I. Inactivation of mitogenesis by interactions with surface immunoglobulin and Fc-receptor molecules. J. Exp. Med. 144, 882-896 (1976).
8. Phillips, N. E. & Parker, D. C. Cross-linking of B lymphocyte Fcγ receptors and membrane immunoglobulin inhibits anti-immunoglobulin- induced blastogenesis. J. Immunol. 132, 627-632 (1984)
9. Amigorena, S., Bonnerot, C., Choquet, D., Fridman, W. H. & Teillaud, J. L. Fcγ RII expression in resting and activated B lymphocytes. Eur. J. Immunol. 19, 1379-1385 (1989).
10. Ravetch, J. V. & Kinet, J. P. Fc receptors. Annu. Rev. Immunol. 9, 457-492 (1991).
11. Daeron, M. et al. Distinct intracytoplasmic sequences are required for endocytosis and phagocytosis via murine Fcγ RII in mast cells. Int. Immunol. 5, 1393-1401 (1993).
12. Qin, D. et al. Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response. J. Immunol. 164, 6268-6275 (2000).
13. Barrington, R. A., Pozdnyakova, O., Zafari, M. R., Benjamin, C. D. & Carroll, M. C. B lymphocyte memory: role of stromal cell complement and FcγRIIB receptors. J. Exp. Med. 196, 1189-1199 (2002).
14. Ravetch, J. V. et al. Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. Science 234, 718-725 (1986).
15. Brooks, D. G., Qiu, W. Q., Luster, A. D. & Ravetch, J. V. Structure and expression of human IgG FcRII (CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J. Exp. Med. 170, 1369-1385 (1989).
16. Stuart, S. G. et al. Human IgG Fc receptor (hFcRII; CD32) exists as multiple isoforms in macrophages, lymphocytes and IgG-transporting placental epithelium. EMBO J. 8, 3657-3666 (1989).
17. Hogarth, P. M. et al. Structure of the mouse βFcγ receptor II gene. J. Immunol. 146, 369-376 (1991).
18. Joshi, T., Ganesan, L. P., Cao, X. & Tridandapani, S. Molecular analysis of expression and function of hFcγRIIbl and b2 isoforms in myeloid cells. Mol. Immunol. 43, 839-850 (2006).
19. Miettinen, H. M., Rose, J. K. & Mellman, I. Fc receptor isoforms exhibit distinct abilities for coated pit localization as a result of cytoplasmic domain heterogeneity. Cell 58, 317-327 (1989).
20. Matter, K., Yamamoto, E. M. & Mellman, I. Structural requirements and sequence motifs for polarized sorting and endocytosis of LDL and Fc receptors in MDCK cells. J. Cell Biol. 126, 991-1004 (1994).
21. Hunziker, W. & Fumey, C. A di-leucine motif mediates endocytosis and basolateral sorting of macrophage IgG Fc receptors in MDCK cells. EMBO J. 13, 2963-2969 (1994).
22. Miettinen, H. M., Matter, K., Hunziker, W., Rose, J. K. & Mellman, I. Fc receptor endocytosis is controlled by a cytoplasmic domain determinant that actively prevents coated pit localization. J. Cell Biol. 11 6, 875-888 (1992).
23. Tartour, E. et al. Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (Fcγ R.) encoded by an alternatively spliced transcript of the Fcγ RII gene. Int. Immunol. 5, 859-868 (1993).
24. Esposito-Farese, M. E. et al. Membrane and soluble Fcγ RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J. Immunol. 155, 1725-1736 (1995).
25. Sautes, C. et al. Soluble Fcγ receptors II (FcγRII) are generated by cleavage of membrane FcγRII. Eur. J. Immunol. 21, 231-234 (1991).
26. Varin, N. et al. Recombinant soluble receptors for the Fcγ portion inhibit antibody production in vitro. Eur. J. Immunol. 19, 2263-2268 (1989).
27. Amigorena, S. et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256, 1808-1812 (1992).
28. Muta, T. et al. A 13-amino-acid motif in the cytoplasmic domain of Fcγ RIIB modulates B-cell receptor signalling. Nature 369, 340. (1994).
29. Malbec, O. et al. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fcγ receptor IIB during negative regulation of mast cell activation. J. Immunol. 160, 1647-1658 (1998).
30. Katsumata, O. et al. Association of FcγRII with low-density detergent-resistant membranes is important for cross-linking-dependent initiation of the tyrosine phosphorylation pathway and superoxide generation. J. Immunol. 167, 5814-5823 (2001).
31. Kwiatkowska, K. & Sobota, A. The clustered Fcγ receptor II is recruited to Lyn-containing membrane domains and undergoes phosphorylation in a cholesterol-dependent manner. Eur. J. Immunol. 31, 989-998 (2001).
32. Ono, M., Bolland, S., Tempst, P. & Ravetch, J. V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB. Nature 383, 263-266 (1996).
33. Ono, M. et al. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 90, 293-301 (1997).
34. Pearse, R. N. et al. SHIP recruitment attenuates Fcγ RIIB-induced B cell apoptosis. Immunity 10, 753-760 (1999).
35. Tzeng, S. J., Bolland, S., Inabe, K., Kurosaki, T. & Pierce, S. K. The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway. J. Biol. Chem. 280, 35247-35254 (2005).
36. Carter, N. A. & Harnett, M. M. Dissection of the signalling mechanisms underlying FcγRIIB-mediated apoptosis of mature B-cells. Biochem. Soc. Trans. 32, 973-975 (2004).
37. Brauweiler, A. M. & Cambier, J. C. Autonomous SHIP-dependent FcγR signaling in pre-B cells leads to inhibition of cell migration and induction of cell death. Immunol. Lett. 92, 75-81 (2004).
38. Kato, I., Takai, T. & Kudo, A. The pre-B cell receptor signaling for apoptosis is negatively regulated by Fcγ RIIB. J. Immunol. 168, 629-634 (2002).
39. + anti-DNA plasma cells. Nature Immunol. 6, 99-106 (2005).
40. Xiang, Z. et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nature Immunol. 8, 419-429 (2007).
41. Takai, T., Ono, M., Hikida, M., Ohmori, H. & Ravetch, J. V. Augmented humoral and anaphylactic responses in Fcγ RII-deficient mice. Nature 379, 346-349 (1996).
42. Brownlie, R. J. et al. Distinct cell-specific control of autoimmunity and infection by FcγRIIb. J. Exp. Med. 205, 883-895 (2008).
43. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
44. Nimmerjahn, F., Bruhns, P., Horiuchi, K. & Ravetch, J. V. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41-51 (2005).
45. Kalergis, A. M. & Ravetch, J. V. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J. Exp. Med. 195, 1653-1659 (2002).
46. Boruchov, A. M. et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 11 5, 2914-2923 (2005).
47. Dhodapkar, K. M. et al. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102, 2910-2915 (2005).
48. Dhodapkar, K. M. et al. Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 204, 1359-1369 (2007).
49. Schifferli, J. A. & Taylor, R. P. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 35, 993-1003 (1989).
50. Bergtold, A., Desai, D. D., Gavhane, A. & Clynes, R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23, 503-514 (2005).
51. Clynes, R. et al. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189, 179-185 (1999).
52. b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189, 187-194 (1999).
53. Clatworthy, M. R. & Smith, K. G. C. FcγRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J. Exp. Med. 199, 717-723 (2004).
54. Zhang, Y. et al. Immune complex/Ig negatively regulate TLR4-triggered inflammatory response in macrophages through Fcγ RIIb-dependent PGE2 production. J. Immunol. 182, 554-562 (2009).
55. van Lent, P. et al. The inhibitory receptor FcγRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcγRI/III but also by efficient clearance and endocytosis of immune complexes. Am. J. Pathol. 163, 1839-1848 (2003).
56. Daeron, M., Malbec, O., Latour, S., Arock, M. & Fridman, W. H. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J. Clin. Invest. 95, 577-585 (1995).
57. Fong, D. C. et al. Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated FcγRIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol. Lett. 54, 83-91 (1996).
58. Kepley, C. L. et al. Negative regulation of FcεRI signaling by FcγRII costimulation in human blood basophils. J. Allergy Clin. Immunol. 106, 337-348 (2000).
59. Malbec, O., Fridman, W. H. & Daeron, M. Negative regulation of c-kit-mediated cell proliferation by Fcγ RIIB. J. Immunol. 162, 4424-4429 (1999). (Pubitemid 29314838)
60. Pricop, L. et al. Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. J. Immunol. 166, 531-537 (2001).
61. van Mirre, E. et al. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcγRII (CD32), is stable over time and unaffected by cytokines. Blood 108, 584-590 (2006).
62. Willcocks, L. C. et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J. Exp. Med. 205, 1573-1582 (2008).
63. Rosales, C. & Brown, E. J. Signal transduction by neutrophil immunoglobulin G Fc receptors. Dissociation of intracytoplasmic calcium concentration rise from inositol 1,4,5-trisphosphate. J. Biol. Chem. 267, 5265-5271 (1992).
64. Zhou, M. J. & Brown, E. J. CR3 (Mac-1, αM ß2, CD11b/CD18) and FcyRIII cooperate in generation of a neutrophil respiratory burst: requirement for FcyRIII and tyrosine phosphorylation. J. Cell Biol. 125, 1407-1416 (1994).
65. Coxon, A. et al. FcyRIII mediates neutrophil recruitment to immune complexes. A mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity 14, 693-704 (2001).
66. Gjertsson, I., Kleinau, S. & Tarkowski, A. The impact of Fcy receptors on Staphylococcus aureus infection. Microb. Pathog. 33, 145-152 (2002).
67. Nakamura, A. et al. Fcy receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. 191, 899-906 (2000).
68. + T helper subsets. J. Immunol. 143, 2133-2141 (1989).
69. Rudge, E. R., Cutler, A. J., Pritchard, N. R. & Smith, K. G. C. Interleukin-4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and FcyRII-mediated B cell suppression. J. Exp. Med. 195, 1079-1085 (2002).
70. Tridandapani, S. et al. Regulated expression and inhibitory function of Fcy RIIb in human monocytic cells. J. Biol. Chem. 277, 5082-5089 (2002).
71. Shushakova, N. et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcyRs in immune complex-induced lung disease. J. Clin. Invest. 110, 1823-1830 (2002).
72. Pritchard, N. R. et al. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcyRII. Curr. Biol. 10, 227-230 (2000).
73. Bonnerot, C. et al. Methylation in the 5' region of the murine ßFcy R gene regulates the expression of Fc y receptor II. J. Immunol. 141, 1026-1033 (1988).
74. Bonnerot, C, Choukroun, V., Marloie, M. A. & Fridman, W. H. Two distinct regions of the mouse ßFcy R gene control its transcription. Immunobiology 185, 222-234 (1992).
75. Hor, S., Ziv, T, Admon, A. & L ehner, P. J. Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. Mol. Cell Proteomics 8, 1959-1971 (2009).
76. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcyRIII complex. Nature 406, 267-273 (2000).
77. Bruhns, P. et al. Specificity and affinity of human Fcy receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725 (2009).
78. Willcocks, L. C, Smith, K. G. & Clatworthy, M. R. Low-affinity Fcy receptors, autoimmunity and infection. Expert Rev. Mol. Med. 11, e24 (2009).
79. Matsumiya, S. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368, 767-779 (2007).
80. Boyd, P. N., Lines, A. C. & Patel, A. K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32, 1311-1318 (1995).
81. Kaneko, Y, Nimmerjahn, F & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
82. Warmerdam, P. A., Nabben, N. M., van de Graaf, S. A., van de Winkel, J. G. & Capel, P. J. The human low affinity immunoglobulin G. Fc receptor IIC gene is a result of an unequal crossover event. J. Biol. Chem. 268, 7346-7349 (1993).
83. Bailey, J. A. et al. Recent segmental duplications in the human genome. Science 297, 1003-1007 (2002).
84. Nimmerjahn, F & Ravetch, J. V. Fc-receptors as regulators of immunity. Adv. Immunol. 96, 179-204 (2007).
85. Rogers, K. A., Scinicariello, F & Attanasio, R. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J. Immunol. 177, 3848-3856 (2006).
86. Zhou, X. J. et al. Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. Int. Immunol. 22, 45-51 (2010).
87. Hastings, P. J., Lupski, J. R., Rosenberg, S. M. & Ira, G. Mechanisms of change in gene copy number. Nature Rev. Genet. 10, 551-564 (2009).
88. Traherne, J. A. et al. Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. Hum. Mol. Genet. 19, 737-751 (2010).
89. Luan, J. J. et al. Defective FcγRII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum. J. Immunol. 157, 4707-4716 (1996).
90. Jiang, Y. et al. Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 51, 429-435 (2000).
91. Xiu, Y. et al. Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. J. Immunol. 169, 4340-4346 (2002).
92. Rahman, Z. S. et al. Expression of the autoimmune Fcgr2b NZW allele fails to be upregulated in germinal center B cells and is associated with increased IgG production. Genes Immun. 8, 604-612 (2007).
93. Hibbs, M. L., Hogarth, P. M. & McKenzie, I. F. The mouse Ly-17 locus identifies a polymorphism of the Fc receptor. Immunogenetics 22, 335-348 (1985).
94. Slingsby, J. H., Hogarth, M. B., Walport, M. J. & Morley, B. J. Polymorphism in the Ly-17 alloantigenic system of the mouse FcgRII gene. Immunogenetics 46, 361-362 (1997).
95. Su, K. et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcγRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J. Immunol. 172, 7186-7191 (2004).
96. Su, K. et al. Expression profile of FcγRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J. Immunol. 178, 3272-3280 (2007).
97. Blank, M. C. et al. Decreased transcription of the human FCGR2B gene mediated by the-343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum. Genet. 11 7, 220-227 (2005).
98. Kyogoku, C. et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. 46, 1242-1254 (2002).
99. Willcocks, L. et al. A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc. Natl Acad. Sci. USA. 12 April 2010 (doi:10.1073/pnas. 0915133107).
100. Floto, R. A. et al. Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts. Nature Med. 11, 1056-1058 (2005).
101. Kono, H. et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14, 2881-2892 (2005).
102. Clatworthy, M. R. et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malariA. Proc. Natl Acad. Sci. USA 104, 7169-7174 (2007).
103. Siriboonrit, U. et al. Association of Fcγ receptor IIb and IIIb polymorphisms with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens 61, 374-383 (2003).
104. Goodnow, C. C., Sprent, J., Fazekas de St. Groth, B. & Vinuesa, C. G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590-597 (2005).
105. Suzuki, Y. et al. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney Int. 54, 1166-1174 (1998).
106. Bolland, S. & Ravetch, J. V. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277-285 (2000).
107. McGaha, T. L., Sorrentino, B. & Ravetch, J. V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590-593 (2005).
108. Wakeland, E. K., Liu, K., Graham, R. R. & Behrens, T. W. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15, 397-408 (2001).
109. Jiang, Y. et al. Genetically determined aberrant down-regulation of FcγRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int. Immunol. 11, 1685-1691 (1999).
110. Paul, E., Nelde, A., Verschoor, A. & Carroll, M. C. Follicular exclusion of autoreactive B cells requires FcγRIIb. Int. Immunol. 19, 365-373 (2007).
111. Li, X. et al. A novel polymorphism in the Fcγ receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum. 48, 3242-3252 (2003).
112. Lau, C. S., Yin, G. & Mok, M. Y. Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus 15, 715-719 (2006).
113. Mackay, M. et al. Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J. Exp. Med. 203, 2157-2164 (2006).
114. Carreno, L. J., Pacheco, R., Gutierrez, M. A., Jacobelli, S. & Kalergis, A. M. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fcγ receptors and costimulatory molecules on dendritic cells. Immunology 128, 334-341 (2009).
115. Blom, A. B., van Lent, P. L., Holthuysen, A. E., Jacobs, C. & van den Berg, W. B. Skewed balance in basal expression and regulation of activating v inhibitory Fcγ receptors in macrophages of collagen induced arthritis sensitive mice. Ann. Rheum. Dis. 62, 465-471 (2003).
116. van Venrooij, W. J., van Beers, J. J. & Pruijn, G. J. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1143, 268-285 (2008).
117. Radstake, T. R. et al. The functional variant of the inhibitory Fcγ receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis. Arthritis Rheum. 54, 3828-3837 (2006).
118. Wenink, M. H. et al. The inhibitory FcγIIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease. J. Immunol. 183, 4509-4520 (2009).
119. Iruretagoyena, M. I. et al. Activating and inhibitory Fcγ receptors can differentially modulate T cell-mediated autoimmunity. Eur. J. Immunol. 38, 2241-2250 (2008).
120. Tackenberg, B. et al. Impaired inhibitory Fcγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl Acad. Sci. USA 106, 4788-4792 (2009).
121. Bruin, M. et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br. J. Haematol. 127, 561-567 (2004).
122. Asahi, A. et al. Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. J. Clin. Invest. 11 8, 2939-2949 (2008).
123. Musher, D. M. et al. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154, 245-256 (1986).
124. Maglione, P. J., Xu, J., Casadevall, A. & Chan, J. Fcγ receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J. Immunol. 180, 3329-3338 (2008).
125. Uppington, H. et al. Effect of immune serum and role of individual Fcγ receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine macrophages. Immunology 11 9, 147-158 (2006).
126. Da Silva, D. M., Fausch, S. C., Verbeek, J. S. & Kast, W. M. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcγ receptors and contributes to acquisition of T cell immunity. J. Immunol. 178, 7587-7597 (2007).
127. Yasuda, K., Sugita, N., Kobayashi, T., Yamamoto, K. & Yoshie, H. FcγRIIB gene polymorphisms in Japanese periodontitis patients. Genes Immun. 4, 541-546 (2003).
128. Kumaratilake, L. M. et al. A synthetic tumor necrosis factor-α agonist peptide enhances human polymorphonuclear leukocyte-mediated killing of Plasmodium falciparum in vitro and suppresses Plasmodium chabaudi infection in mice. J. Clin. Invest. 95, 2315-2323 (1995).
129. Muniz-Junqueira, M. I., dos Santos-Neto, L. L. & Tosta, C. E. Influence of tumor necrosis factor-α on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro. Cell. Immunol. 208, 73-79 (2001).
130. Kwiatkowski, D. P. How malaria has affected the human genome and what human genetics can teach us about malariA. Am. J. Hum. Genet. 77, 171-192 (2005).
131. + thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of KenyA. Blood 106, 368-371 (2005).
132. Wijngaarden, S. et al. A shift in the balance of inhibitory and activating Fcγ receptors on monocytes toward the inhibitory Fcγ receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum. 50, 3878-3887 (2004).
133. Negi, V. S. et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 27, 233-245 (2007).
134. Debre, M. et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpurA. Lancet 342, 945-949 (1993).
135. Samuelsson, A., Towers, T. L. & Ravetch, J. V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-486 (2001).
136. Crow, A. R. et al. IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102, 558-560 (2003).
137. Kaneko, Y., Nimmerjahn, F., Madaio, M. P. & Ravetch, J. V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203, 789-797 (2006).
138. Bruhns, P., Samuelsson, A., Pollard, J. W. & Ravetch, J. V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18, 573-581 (2003).
139. Anthony, R. M., Wermeling, F., Karlsson, M. C. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA 105, 19571-19578 (2008).
140. Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nature Med. 12, 688-692 (2006).
141. Routier, F. H. et al. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods. J. Immunol. Methods 213, 113-130 (1998).
142. Belostocki, K. et al. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcγ receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum. 58, 384-388 (2008).
143. Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754-758 (2002).
144. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
145. Zhang, Z., Zhang, M., Ravetch, J. V., Goldman, C. & Waldmann, T. A. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102, 284-288 (2003). (Pubitemid 36759666)
146. Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (2004).
147. Shields, R. L. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591-6604 (2001).
148. Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103, 4005-4010 (2006).
149. Ferrara, C., Stuart, F., Sondermann, P., Brunker, P. & Umana, P. The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281, 5032-5036 (2006).
150. Rankin, C. T. et al. CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphomA. Blood 108, 2384-2391 (2006).
151. Zhou, P. et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 111, 3403-3406 (2008).
152. Tam, S. W., Demissie, S., Thomas, D. & Daeron, M. A bispecific antibody against human IgE and human FcγRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 59, 772-780 (2004).
153. Allen, L. C., Kepley, C. L., Saxon, A. & Zhang, K. Modifications to an Fcγ-Fcε fusion protein alter its effectiveness in the inhibition of FcεRI-mediated functions. J. Allergy Clin. Immunol. 120, 462-468 (2007).
154. Mertsching, E. et al. A mouse Fcγ-Fcepsilon protein that inhibits mast cells through activation of FcγRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J. Allergy Clin. Immunol. 121, 441-447 e445 (2008).
155. Van Scott, M. R. et al. Systemic administration of an Fcγ-Fcε-fusion protein in house dust mite sensitive nonhuman primates. Clin. Immunol. 128, 340-348 (2008).
156. Werwitzke, S. et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32). Ann. Rheum. Dis. 67, 154-161 (2008).
157. Wandstrat, A. E. et al. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity 21, 769-780 (2004).
158. Jorgensen T. N. et al. Development of murine lupus involves the combined genetic contribution of the SLAM and FcγR intervals within the Nba2 autoimmune susceptibility locus. J. Immunol. 184,775-786 (2010).
159. Bygrave, A. E. et al. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol. 2, e243 (2004).
160. Carlucci, F. et al. Genetic dissection of spontaneous autoimmunity driven by 129-derived chromosome 1 loci when expressed on C57BL/6 mice. J. Immunol. 178, 2352-2360 (2007).
161. Bickerstaff, M. C. et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nature Med. 5, 694-697 (1999).
162. Wu, X. et al. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J. Immunol. 169, 1587-1592 (2002).
163. Botto, M. C1q knock-out mice for the study of complement deficiency in autoimmune disease. Exp. Clin. Immunogenet. 15, 231-234 (1998).
164. Sohn, H. W., Pierce, S. K. & Tzeng, S. J. Live cell imaging reveals that the inhibitory FcγRIIB destabilizes B cell receptor membrane-lipid interactions and blocks immune synapse formation. J. Immunol. 180, 793-799 (2008).
165. Liu, W., Sohn, H. W., Tolar, P., Meckel, T. & Pierce, S. K. Antigen-induced oligomerization of the B cell receptor is an early target of FcγRIIB inhibition. J. Immunol. 184, 1977-1989 (2010).
166. El Shikh M. E., El Sayed R., Szakal A. K. & Tew J. G. Follicular dendritic cell (FDC)-FcγRIIB engagement via immune complexes induces the activated FDC phenotype associated with secondary follicle development. Eur. J. Immunol. 36, 2715-2724 (2006).